Open innovation is often suggested as a solution to enhance productivity in under-performing areas of research. Now, the strengths and weaknesses of a new open innovation model in drug discovery have been evaluated.
An independent evaluation of the Structural Genomics Consortium (SGC) examined the strengths and weaknesses of its efforts to support drug discovery efforts through a unique, open access model of public-private collaboration.
Dr. Gill Samuels CBE joined the RAND Europe Council of Advisors during its meeting in January. She is a physiologist and neuropharmacologist by training and was Director of Cardiovascular Biology at Pfizer, contributing to the discovery and development of a number of medicines.
Applications are being accepted now through March 21 for the 21st annual RAND Summer Institute (RSI), a pair of conferences on aging that will be held next July 7–10 at the RAND Corporation headquarters in Santa Monica.
Antimicrobial drugs are no longer working as they once did. The bugs that they are supposed to attack are becoming increasingly resistant. Microbes follow the same rules of evolution as we do. Through reproduction and natural selection the fittest survive.
This exploratory study investigates the characteristics of publications cited on clinical guidelines, and the funding sources they acknowledge, in order to better understand how research is translated into changes in policy and practice.
Project Retrosight analysed 29 case studies of cardiovascular and stroke research in Australia, Canada, and the UK, and found that clinical research has greater societal impact over a 15-20 year timescale, while basic research has greater academic impact.
Project Retrosight analyzed 29 case studies of cardiovascular and stroke research in Australia, Canada, and the UK, and found that clinical research has greater societal impact over a 15–20 year timescale, while basic research has greater academic impact.
Project Retrosight analysed 29 case studies of cardiovascular and stroke research in Australia, Canada and the UK, examining the diversity of impact produced by this kind of research and identifying factors associated with various levels of payback.
This comparative analysis of English and U.S. forensic DNA databases and profiling attempted to confirm what many senior U.S. law enforcement officials believe: that the English criminal justice system has capitalized more fully on the crime-fighting potential of DNA evidence.
In innovative sectors, investments in knowledge creation by one party often result in "spillovers": external benefits for other parties. A high-level forum organised and facilitated by the Office of Health Economics and RAND Europe explored strategies to reap the benefits of such spillover effects from biomedical and health research in the UK, and how to consider these effects more explicitly during the policymaking process.
This documented briefing provides an overview of the European Research Area and explores whether such an integrated research area exists in health and biomedical research. The report is supported by the Department of Health (England).